AIVL, the Australian Injecting and Illicit Drug Users League, is the national peer-led peak organisation representing our network of peer-based harm reduction and Drug User Organisations. AIVL’s primary role is to elevate the voices of people affected by hepatitis C/people who inject drugs in Australia, develop the harm reduction peer workforce, and develop policy and program informed by people with lived-living experience of hepatitis C. AIVL, the Australian Injecting and Illicit Drug Users League, was formed in the late 1980s by a group of people with experience of illicit drug use and injecting drug use, many of them involved in state and territory Drug User Organisations (DUOs), that came together, during the HIV health crisis of the early to mid-1980s, to coordinate the development of a consolidated PWUD voice at a national level. AIVL is funded through the Australian Department of Health and Aged Care as the peer-led hepatitis C response peak organisation. AIVL was the first organisation to express the situation with hepatitis C affecting people who inject drugs in Australia. For over 30 years, AIVL has led the hepatitis C response nationally, advised the department, and ensured the roll out of peer education programs, resources, and services promoting DAA to our communities. AIVL also supported the work of lived-living network in the Asia-Pacific region in collaboration with DFAT. The members of the AIVL network are service-delivery state and national organisations tackling hepatitis C and improving the health and wellbeing of our communities.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close